Hengrui Medicine gains approval for clinical drug trial

Jiangsu Hengrui Medicine announced that its subsidiary, Guangdong Hengrui Pharmaceutical, has received approval from the National Medical Products Administration (NMPA) for clinical trials of SHR-2173 injection, indicated for primary membranous nephropathy. The company's independently developed biological product targets abnormally activated immune cells, aiming to reduce autoantibody levels and improve patient outcomes. As of now, there are no similar drugs available on the market, or in the clinical research phase, either domestically or internationally. Cumulative R&D investment in the SHR-2173 injection project totals approximately CNY 64.07 million. While this approval allows the company to proceed to clinical trials, the company cautions that the drug still requires further review and approval before commercialization.